- Laryngeal cancer is a cancer that affects the throat
- Smoking and high alcohol consumption are important risk factors
- The optimal treatment for laryngeal cancer is based on neoadjuvant chemotherapy for select patients
The
use of neoadjuvant chemotherapy for a selection of patients for the treatment they are most likely to
respond to has been suggested by a research team from University of Michigan
Comprehensive Cancer Center. Their research was published in the JAMA Otolaryngology - Head and Neck Surgery.
The larynx is the voice
box in the throat which contains the vocal cords that move and vibrate to
produce sounds. Smoking and excessive alcohol intake particularly increase the
risk for cancer of the larynx. Though surgery, radiation and chemotherapy are available for its treatment,
the outcomes are not very good especially for advanced cases. The chances of survival for early stage
cancers are 60 to 90%, while that for later stages are between 50 to 60%.
A partial surgical removal of the larynx preserves the voice, but a total laryngectomy results in loss of the ability to speak and affects the quality of life of the patient. Though radiotherapy and chemotherapy can preserve the larynx, the survival rates following these treatments for advanced laryngeal cancer are not as good as compared to those for primary surgery.
Among the patients with stage 3 and stage 4 laryngeal cancer:
- 71 out of the 153 patients received neoadjuvant chemotherapy with cisplatin and fluorouracil or carboplatin. The remaining patients directly opted for surgery or chemo-radiation
- If the patients had a partial response to neoadjuvant chemotherapy, that is, more than 50% reduction in the size of the tumor, they were administered definitive chemo-radiotherapy
- If they did not respond based on the size of the tumor on endoscopy and CT/MRI images, they underwent total laryngectomy followed by radiation
- The patients were followed up weekly for a period of 48 months
- Following neoadjuvant treatment, 22% patients received chemo-radiotherapy while the remaining required laryngectomy
- Primary surgery and selection of patients based on neoadjuvant treatment improved overall survival (OS) and disease-specific survival (DSS) as compared to the use of primary chemo-radiotherapy
- The 5-year disease - specific survival (DSS) for advanced laryngeal cancer with neoadjuvant treatment was around 80%. It was much better than in those who underwent primary chemo-radiotherapy (66%)
- Those who underwent primary chemo-radiotherapy had the highest rate of preservation of the larynx. It must however be remembered that chemo-radiotherapy may affect the function of the larynx over a longer duration and could result in symptoms of difficulty with swallowing and chronic aspiration.
- Patients who underwent primary laryngectomy and salvage laryngectomy did well, and better than those who underwent definitive chemo-radiotherapy therefore reiterating the important role of surgery in the treatment of advanced laryngeal cancer
- Most patients experienced mild adverse effects during treatment with the neoadjuvant chemotherapy. One patient however, suffered from liver failure.
References :
- Wolf G et al. Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2016.3669
- Laryngeal Cancer Treatment (PDQ®)-Patient Version - (https://www.cancer.gov/types/head-and-neck/patient/laryngeal-treatment-pdq)
Advertisement
|
Recommended Reading
Latest Health In Focus




